![William Sibold](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
William Sibold
Chief Executive Officer at
MADRIGAL PHARMACEUTICALS, INC.
Net worth: 4 M $ as of 31/05/2026
Profile
William J.
Sibold is Chief Executive Officer at True North Therapeutics, Inc., President, Chief Executive Officer & Director at Madrigal Pharmaceuticals, Inc. since 2023, President & Director at Bioverativ Therapeutics, Inc., and Director at Biotechnology Innovation Organization.
Former positions include Chief Executive Officer at Lycera Corp., President & Director at Genzyme Corp., Product Manager at Amgen, Inc., Senior Vice President-US Commercial Division at Biogen, Inc., Chief Commercial Officer & Senior Vice President at Avanir Pharmaceuticals, Inc., EVP-Specialty Care & President-North America at Sanofi from 2017 to 2023, Principal at Eli Lilly Canada, Inc., and President at Bioverativ, Inc. Education includes undergraduate studies at Yale University and an MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/04/2026 | 8,310 ( 0.04% ) | 4 M $ | 31/05/2026 |
William Sibold active positions
| Companies | Position | Start |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Chief Executive Officer | 08/09/2023 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Director/Board Member | - |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | President | - |
True North Therapeutics, Inc.
 True North Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies that selectively inhibit the complement system to treat rare diseases | Chief Executive Officer | - |
Former positions of William Sibold
| Companies | Position | End |
|---|---|---|
| SANOFI | Corporate Officer/Principal | 31/08/2023 |
| AMGEN INC. | Corporate Officer/Principal | - |
| BIOVERATIV INC | President | - |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | President | - |
| AVANIR PHARMACEUTICALS INC | Corporate Officer/Principal | - |
Training of William Sibold
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
75
1st degree connections
14
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 14 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products for the treatment of nervous system disorder | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Lycera Corp.
 Lycera Corp. Pharmaceuticals: MajorHealth Technology Develops novel oral medicines for treating autoimmune diseases and cancer | Health Technology |
Eli Lilly Canada, Inc.
 Eli Lilly Canada, Inc. Pharmaceuticals: MajorHealth Technology Pharmaceuticals, drugs, chemicals | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
True North Therapeutics, Inc.
True North Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies that selectively inhibit the complement system to treat rare diseases | Health Technology |
Madrigal Pharmaceuticals, Inc.
 Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that engages in discovery, research, development and commercialization of therapies for hemophilia & blood disorders | Health Technology |
- Stock Market
- Insiders
- William Sibold
